Diabetic macular edema (DME) has been diagnosed more frequently as detection methods have improved. For Type 1 patients who are diagnosed at an early age, disease management begins at the time of diagnosis, and blood sugar (BS) control is critical to the prevention of secondary microvascular complications. It has been documented that nearly all Type 1 diabetics develop significant retinal disease in the two decades following their initial diagnosis. Baseline retinal disease in these patients has been shown to be a clear prognostic factor for the incidence of vision threatening retinal disease later in life. Type 2 diabetics who showed no retinal disease at diagnosis have lower risk of progression toward retinal disease in the same time period. When a patient is diagnosed with diabetic macular edema (DME), microvascular disease is already evident as clearly shown in multimodality ultra-widefield (200 degrees) or UWF™ retinal imaging with optomap®. This has been confirmed by UWF fluorescein angiography (FA).
Rapid visualization of the peripheral retina with UWF color and FA imaging (often without a mydriatic agent) allows more pathology to be found at an earlier onset. Peripheral ischemia is determined with confirmatory FA which documents peripheral neovascularization, nonperfusion, and late peripheral vascular leakage. Earlier diagnosis allows earlier treatment. Thus, …![]()